扎鲁司特对治疗哮喘减少吸入激素剂量的评价

Evaluation of the therapeutic effects of zafirlukast in asthma patients during reduction of high-dose inhaled corticosteroid

目的 评价重度慢性哮喘患者在减少吸入激素剂量期间加服扎鲁司特的临床疗效。方法 34例接受高剂量吸入激素治疗的重度慢性哮喘患者随机分为两组 :扎鲁司特组和对照组。观察吸入激素剂量减半同时加口服扎鲁司特后肺功能 (FEV1 与PEFR)和每周按需使用 β2 激动剂次数的变化 ,时间 4周。结果 扎鲁司特组患者第 4周末的肺功能及按需使用 β2 激动剂的次数无明显变化。但对照组肺功能明显恶化 ,因症状加重而需使用 β2 激动剂的次数明显增多。结论 激素减量吸入同时加服扎鲁司特并不引起哮喘病情的恶化 。

Objective To evaluate clinical efficacy of leukotrieneantagonist (zafirlukast) in the prevention of exacerbation of asthma during a reduction of high dose inhaled corticosteroid.Method Thirty four cases with chronic asthma who received high dose inhaled corticosteroid were randomly divided into two groups: zafirlukast group and control group. Changes of Lung functions (FEV 1 and PEFR) were observed,along with the number of uses of β 2 agonist weekly in patients with half dose inhaled corticosteroid and oval zafirlukast.Results After 4 weeks, lung functions and the number of use of β 2 agonist remained unchanged in the zafirlukast group.In the control group, however, FEV 1 and OEFR decreased significantly and the number of use of β 2 agonist weekly increased markedly.Conclusion Dosage of inhaled corticosteroid can be reduced by adding xafirlukast without apparent exacerbations of asthma.